Related Experiment Video
Updated: Jun 17, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Glioma-associated cancer-initiating cells induce immunosuppression
Jun Wei1, Jason Barr, Ling-Yuan Kong
1Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Purpose:
Glioblastoma multiforme is a lethal cancer that responds poorly to therapy. Glioblastoma multiforme cancer-initiating cells have been shown to mediate resistance to both chemotherapy and radiation; however, it is unknown to what extent these cells contribute to the profound immunosuppression in glioblastoma multiforme patients and if strategies that alter their differentiation state can reduce this immunosuppression.
Experimental Design:
We isolated a subpopulation of cells from glioblastoma multiforme that possessed the capacity for self-renewal, formed neurospheres in vitro, were capable of pluripotent differentiation, and could initiate tumors in vivo. The immune phenotype of these cells was characterized including the elaboration of immunosuppressive cytokines and chemokines by ELISA. Functional immunosuppressive properties were characterized based on the inhibition of T-cell proliferation and effector responses, triggering of T-cell apoptosis, and induction of FoxP3(+) regulatory T cells. On altering their differentiation state, the immunosuppressive phenotype and functional assays were reevaluated.
Results:
We found that the cancer-initiating cells markedly inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis that was mediated by B7-H1 and soluble Galectin-3. These immunosuppressive properties were diminished on altering the differentiation of the cancer-initiating cells.
Conclusion:
Cancer-initiating cells contribute to tumor evasion of the immunosurveillance and approaches that alter the differentiation state may have immunotherapeutic potential.
Insights
Glioblastoma cancer-initiating cells suppress the immune system. Altering their differentiation state reduces this immunosuppression, suggesting potential immunotherapeutic strategies for glioblastoma multiforme.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Stem Cell Biology
Background:
- Glioblastoma multiforme is an aggressive brain tumor with poor therapeutic response.
- Cancer-initiating cells in glioblastoma multiforme are implicated in treatment resistance.
- The role of these cells in glioblastoma-associated immunosuppression is not fully understood.
Purpose of the Study:
- To investigate the contribution of glioblastoma cancer-initiating cells to immunosuppression.
- To determine if modulating their differentiation state can reduce immunosuppression.
Main Methods:
- Isolation and characterization of glioblastoma cancer-initiating cells.
- Assessment of immune phenotype, including cytokine/chemokine production.
- Functional assays evaluating T-cell proliferation, apoptosis, and regulatory T-cell induction.
- Reevaluation after altering cancer-initiating cell differentiation.
Main Results:
- Glioblastoma cancer-initiating cells significantly inhibit T-cell proliferation and activation.
- These cells induce regulatory T cells and T-cell apoptosis, mediated by B7-H1 and Galectin-3.
- Altering the differentiation state of cancer-initiating cells diminished their immunosuppressive effects.
Conclusions:
- Glioblastoma cancer-initiating cells contribute to immune evasion in glioblastoma multiforme.
- Strategies targeting the differentiation state of these cells hold potential for glioblastoma immunotherapy.
Related Concept Videos
Tumor Immunotherapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
